Gai Liu
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$7.3MFederal grants as PI16 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $7.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 19, 2026 | NIH | STTR Phase II Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral | $969K | MICROBIOTIX, INC. |
| May 16, 2025 | NIH | STTR Phase II Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral | $977K | MICROBIOTIX, INC. |
| Jul 22, 2024 | NIH | SBIR Phase I Development of antibody drug conjugates as pan-filo antivirals | $287K | MICROBIOTIX, INC. |
| Aug 21, 2023 | NIH | SBIR Phase I Development of antibody drug conjugates as pan-filo antivirals | $300K | MICROBIOTIX, INC. |
| Jul 11, 2023 | NIH | STTR Phase I Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy | $272K | MICROBIOTIX, INC. |
| Aug 12, 2022 | NIH | STTR Phase I Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy | $297K | MICROBIOTIX, INC. |
| Aug 12, 2022 | NIH | STTR Phase I Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy | $569K | MICROBIOTIX, INC. with WASHINGTON UNIVERSITY |
| Nov 19, 2020 | NIH | SBIR Phase I Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy | $300K | MICROBIOTIX, INC. |
| Dec 9, 2019 | NIH | SBIR Phase I Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy | $300K | MICROBIOTIX, INC. |
| Dec 9, 2019 | NIH | SBIR Phase I Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy | $600K | MICROBIOTIX, INC. |
| Jul 22, 2019 | NIH | SBIR Phase I Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection | $298K | MICROBIOTIX, INC. |
| Nov 30, 2018 | NIH | SBIR Phase I Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy | $296K | MICROBIOTIX, INC. |
| Sep 4, 2018 | NIH | SBIR Phase I Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection | $300K | MICROBIOTIX, INC. |
| Sep 4, 2018 | NIH | SBIR Phase I Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection | $598K | MICROBIOTIX, INC. |
| Jan 15, 2018 | NIH | SBIR Phase I Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy | $596K | MICROBIOTIX, INC. |
| Jan 5, 2018 | NIH | SBIR Phase I Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy | $299K | MICROBIOTIX, INC. |
Peer ranks
Federal funding#133
Awards as PI#37
Patents#273
Companies
- MICROBIOTIX, INC.Linked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.